Kirill Dmitriev, the head of the Russian Direct Investment Fund (RDIF), has announced the timing of approval for the use of the Russian Sputnik V coronavirus vaccine in Europe. His speach are quoted by TASS.
According to him, the drug may be approved for use in the European Union at the end of February or March.
“We have submitted documents for approval to the European Medical Association, which is a European regulator,” Dmitriev said.
Earlier in the medical journal Lancet, data appeared that the results of the third phase of clinical trials of the Russian Sputnik V vaccine demonstrated 91.6% effectiveness against coronavirus. 19,866 people took part in testing the vaccine.
Sputnik V became the world’s first registered vaccine based on the human adenovirus. Currently, the development of Russian scientists is among the ten best vaccine candidates in the list of the World Health Organization (WHO).